Vifor Pharma has pledged to pay £23 million to the NHS after Britain’s competition watchdog raised concerns the drugs firm had been making misleading claims about the safety of a rival’s iron ...

On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain's Sanifit and fellow Swiss biotech Inositec for a combined value of €225 ...

If accepted, Vifor Pharma's £23m offer will "claw back" money for the NHS and close the CMA's first-ever disparagement case.

After recently taking steps to undo messaging about a rival product in the EU, CSL Vifor is carrying its amends campaign west to the U.K. Following an investigation launched earlier this year by ...

Vifor Pharma has agreed to pay £23m to the NHS after being accused by Britain's competition watchdog of making false safety claims about a competitor's iron deficiency treatment. The Competition ...

The UK’s Competition and Markets Authority (CMA) has received a £23m ($29m) offer from Vifor Pharma for the NHS to address competition concerns that the regulator has been investigating.

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...